Image Image Image Image Image Image Image Image Image

COVID-19 and Epilepsy Fact Sheet

While most people who may develop COVID-19 (novel coronavirus) will have only mild to moderate symptoms, some people may need to see a health care provider or be hospitalized. The focus by the Centers for Disease Control and Prevention (CDC), and all of us, is on slowing down the spread of COVID-19 and ensuring people can receive the care they need. The word “community mitigation” is used to describe the process of slowing down the spread of the virus. Each community is or will be offering guidance for their area, and the CDC has updated recommendations about what people and community leaders should know and do.

Below is a fact sheet with the latest answers to questions you have been asking us about COVID-19 and epilepsy. We will continue to update this page as new data reveals more information.

Download An Updated Fact Sheet Answering Frequently Asked Questions

Listen to a recent interview between EFWA Executive Director, Kevin Koppes and 2 local Epileptologists as they discuss epilepsy and COVID-19



COVID-19 Information & Resources from Pharmaceutical Companies:

*In light of the COVID-19 outbreak, Eisai is monitoring our global supply chain resources to safeguard an adequate supply of our medicines. There are no issues with the supply of materials or their source, and we do not anticipate any issues at this time.


Patient Assistance Fycompa


Patient Assistance Banzel:

Banzel is offered through Rx Outreach for patients who qualify for free medicine



UCB is committed to helping patients in the U.S. experiencing hardship due to the #COVID19 pandemic. If you’ve been impacted by job loss, furlough, or health insurance coverage loss, contact ucbCARES to qualify for your prescribed UCB medicines at no cost:


We know that some patients and their caregivers may be facing financial or employment insecurity during these uncertain times. To ensure that your patients continue to receive their treatment, we are offering extended copay assistance for EPIDIOLEX® (cannabidiol) CV.

At this time, we are extending our Copay Savings Program to offer commercially insured patients $0 copays for prescriptions filled between April 1, 2020 and September 30, 2020. In addition, there will be no annual savings cap for the 2020 calendar year. These changes are intended to improve patient access and will take effect on April 1, 2020. Please find the copay card HERE.

We are closely monitoring our supply chain for EPIDIOLEX® and, at this time, do not foresee any supply interruptions in the United States.

Greenwich Biosciences also offers support for eligible patients with no insurance or not enough insurance to cover their prescription. Patients and caregivers, including those whose situations have changed as a result of the COVID-19 pandemic, can access available resources through the Epidiolex Engage™ program.

For more information, please contact Epidiolex Engage at 1-833-GBNGAGE (1-833-426-4243). Learn more about updates to the copay savings program at


Other COVID Resources: